Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
OPERATING ACTIVITIES
Net loss	$ (5,504)	$ (3,522)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	2,319	512
Depreciation	23	27
Change in fair value of warrant liability		(2)
Changes in operating assets and liabilities:
Prepaid research and development	15
Prepaid expenses and other current assets		198
Deferred financing costs	66	(173)
Other long-term assets	(62)
Accounts payable	(310)	823
Accrued and other current liabilities	894	483
Net cash used in operating activities	(2,559)	(1,654)
INVESTING ACTIVITIES
Purchases of short-term investments	(2,523)
Purchases of property, plant, and equipment	(11)	(8)
Net cash used in investing activities	(2,534)	(8)
FINANCING ACTIVITIES
Proceeds from issuance of common stock	5,992	5,060
Net cash provided by financing activities	5,992	5,060
Net increase in cash and cash equivalents	899	3,398
Cash and cash equivalents at the beginning of the year	1,241	1,292
Cash and cash equivalents at the end of the period	2,140	4,690
Supplemental disclosure of non-cash activities:
Settlement of contingency matter		(3,250)
Settlement of due to Harvard Bioscience included in accrued and other current liabilities		(750)
Issuance of Series E convertible preferred stock		4,000
Purchases of property and equipment in accounts payable or accrued expenses	5
Preferred stock dividends	77	18
Conversion of preferred stock into common stock	$ 4,257